Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CASI CASI Pharmaceuticals	$1.20 -7.7%	$1.78	$1.10 ▼ $7.67	$15.99M	0.66	54,817 shs	30,569 shs
FLGC Flora Growth	$0.61 -2.9%	$0.65	$0.42 ▼ $2.11	$14.18M	2.04	273,008 shs	95,973 shs
GELS Gelteq	$1.81 -3.7%	$1.83	$0.77 ▼ $5.50	$17.74M	N/A	4.02 million shs	97,815 shs
VIVS VivoSim Labs	$1.47 +3.5%	$0.00	$1.41 ▼ $21.96	$3.69M	1.03	63,196 shs	21,817 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CASI CASI Pharmaceuticals	-7.69%	-9.43%	-35.31%	-44.32%	-66.39%
FLGC Flora Growth	-2.88%	-7.41%	-11.39%	-6.15%	-39.60%
GELS Gelteq	-3.72%	+13.13%	+8.38%	+72.38%	+180,999,900.00%
VIVS VivoSim Labs	+3.52%	+0.68%	-23.44%	+146,999,900.00%	+146,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CASI CASI Pharmaceuticals	4.5546 of 5 stars	3.5	5.0	0.0	4.3	3.8	1.7	0.0
FLGC Flora Growth	3.0028 of 5 stars	3.3	5.0	0.0	0.0	3.0	0.8	0.6
GELS Gelteq	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VIVS VivoSim Labs	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CASI CASI Pharmaceuticals	3.00	Buy	$4.00	233.33% Upside
FLGC Flora Growth	2.50	Moderate Buy	$4.00	555.74% Upside
GELS Gelteq	0.00	N/A	N/A	N/A
VIVS VivoSim Labs	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VIVS, CASI, FLGC, and GELS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/19/2025	CASI CASI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/9/2025	CASI CASI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $4.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CASI CASI Pharmaceuticals	$28.54M	0.52	N/A	N/A	$0.12 per share	10.00
FLGC Flora Growth	$59.51M	0.23	N/A	N/A	$0.31 per share	1.97
GELS Gelteq	$100K	170.86	N/A	N/A	N/A	∞
VIVS VivoSim Labs	$140K	27.30	N/A	N/A	$5.54 per share	0.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CASI CASI Pharmaceuticals	-$39.26M	-$2.55	N/A	∞	N/A	-129.05%	-972.55%	-77.33%	8/15/2025 (Estimated)
FLGC Flora Growth	-$15.91M	-$0.98	N/A	N/A	N/A	-24.85%	-216.49%	-45.56%	8/11/2025 (Estimated)
GELS Gelteq	-$2.33M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
VIVS VivoSim Labs	-$2.48M	-$10.20	N/A	∞	N/A	-1,725.00%	-46.87%	-28.62%	N/A

Latest VIVS, CASI, FLGC, and GELS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/16/2025	Q1 2025	CASI CASI Pharmaceuticals	-$0.61	-$0.69	-$0.08	-$0.69	$7.39 million	$6.24 million
5/13/2025	Q1 2025	FLGC Flora Growth	-$0.01	-$0.04	-$0.03	-$0.04	$14.79 million	$11.79 million
3/31/2025	Q4 2024	CASI CASI Pharmaceuticals	-$0.60	-$0.79	-$0.19	-$0.79	$7.39 million	$13.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CASI CASI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FLGC Flora Growth	N/A	N/A	N/A	N/A	N/A
GELS Gelteq	N/A	N/A	N/A	N/A	N/A
VIVS VivoSim Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CASI CASI Pharmaceuticals	N/A	0.81	0.68
FLGC Flora Growth	0.88	1.05	0.67
GELS Gelteq	N/A	N/A	N/A
VIVS VivoSim Labs	N/A	3.25	3.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CASI CASI Pharmaceuticals	22.23%
FLGC Flora Growth	36.01%
GELS Gelteq	N/A
VIVS VivoSim Labs	8.23%

Insider Ownership

Company	Insider Ownership
CASI CASI Pharmaceuticals	21.24%
FLGC Flora Growth	12.56%
GELS Gelteq	N/A
VIVS VivoSim Labs	3.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CASI CASI Pharmaceuticals	180	12.30 million	9.69 million	Optionable
FLGC Flora Growth	280	22.57 million	19.73 million	Not Optionable
GELS Gelteq	N/A	9.44 million	N/A	N/A
VIVS VivoSim Labs	20	2.60 million	2.50 million	N/A

VIVS, CASI, FLGC, and GELS Headlines

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge
By Jeffrey Neal Johnson | June 4, 2025
View Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge
Astera Labs: AI Infrastructure Play With Significant Growth Ahead
By Nathan Reiff | June 26, 2025
View Astera Labs: AI Infrastructure Play With Significant Growth Ahead

VIVS, CASI, FLGC, and GELS Company Descriptions

CASI Pharmaceuticals NASDAQ:CASI

$1.20 -0.10 (-7.69%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.23 +0.03 (+2.50%)

As of 06/27/2025 05:16 PM Eastern

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Flora Growth NASDAQ:FLGC

$0.61 -0.02 (-2.88%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.62 +0.01 (+1.48%)

As of 06/27/2025 07:59 PM Eastern

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.

Gelteq NASDAQ:GELS

$1.81 -0.07 (-3.72%)

As of 06/27/2025 04:00 PM Eastern

Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.

VivoSim Labs NASDAQ:VIVS

$1.47 +0.05 (+3.52%)

As of 06/27/2025 04:00 PM Eastern

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time